Having as recently as June been sub 50p, shares in self-styled “a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases” Silence Therapeutics (SLN) spiked above 100p in July on the back of announcements of a collaboration with, and investment from, Mallinckrodt (NYSE - MNK). The shares have in the last month sparked significantly further – to a current near 400p, giving a more than £300 million market cap. However…









